Table 1.
Summary of clinical and select pre-clinical studies of regional delivery of CAR-T cells.
| Author | Cancer | Study Type | CAR | Stimulatory Signal | Inhibitory Signal | Additional Therapy | Delivery Method |
|---|---|---|---|---|---|---|---|
| Yaghoubi et al. [19] | Glioblastoma | Clinical Phase I | IL13Rα2 | - | - | Surgical Resection | Catheter infusion into resection cavity |
| Brown et al. [12] | Glioblastoma | Clinical Phase I | IL13Rα2 | - | - | Surgical Resection | Catheter infusion into resection cavity |
| Brown et al. [13] | Glioblastoma | Clinical Phase I | IL13Rα2 | CD137 | IgG4-Fc mutant A | Surgical Resection | Catheter infusion into resection cavity |
| Katz et al. [17] | Hepatic colorectal metastases | Clinical Phase I | CEA | IL2 | - | Chemotherapy | Hepatic artery infusion |
| Katz et al. [26] | Hepatic colorectal metastases | Clinical Phase I | CEA | IL2 | - | Chemotherapy + Yttrium spheres | Hepatic Artery Infusion |
| van Schalkwyk et al. [31] | Head and Neck | Clinical Phase I | T1E28z (ErbB) B | Cytokine receptor 4αβ C | - | Cyclophoshamide | Ultrasound guided intratumoral injection |
| Adusumilli et al. [29] | Pleural Mesothelioma | Clinical Phase I | M28z D | CD28 | - | - | Intrapleural |
| Katz et al. [18] | Peritoneal carcinomatosis | Pre-clinical | CEA | IL2 | Anti-PDL1 Anti-Gr1 Anti-GITR E | - | Intraperitoneal |
| Adusumilli et al. [11] | Pleural Mesothelioma | Pre-clinical | M28z | CD28 | - | Cyclophosphamide | Intrapleural |
| van der Stegen et al. [28] | Head and Neck | Pre-clinical | T1E28z (ErbB) | Cytokine receptor 4αβ C | - | - | Intraperitoneal |
| Davies et al. [30] | Head and Neck | Pre-clinical | T1E28z (ErbB) | Cytokine receptor 4αβ F | - | - | Intraperitoneal |
| Klampatsa et al. [27] | Mesothelioma | Pre-clinical | T1E28z (ErbB) | Cytokine receptor 4αβ | - | - | Intraperitoneal |
A Fc region mutation to reduce the off-target Fc receptor interactions. B A chimeric antigen formed by transforming growth factor-α and epidermal growth factor that recognizes several ErbB dimers. C Chimeric cytokine receptor between IL-4 receptor α ectodomain and IL-2/IL-15 β chain allowing for ex vivo growth stimulation with IL-4 treatment. D Mesothelin specific single-chain variable fragment with CD28/CD3ζ signaling domains. E Anti-Programmed dealth-ligand 1, Anti-Granulocyte Receptor 1, Anti-Glucocorticoid induced tumor necrosis factor receptor 1. F IL-4 administered in vivo rather than ex vivo.